In this article from Update magazine (November/December 2011), Robert A. Rhoades, Vice President, Quality & Compliance Consulting, Quintiles, explains why biopharmaceutical companies can no longer afford to take a traditional compliance approach in a heightened regulatory environment.

Reprinted with permission from FDLI.